Soru

Zorluk: ZorNeoplastic Processes

Match each patient's clinical and histopathologic presentation with the primary molecular mechanism driving their underlying neoplastic process.

  • A 65-year-old man presents with generalized lymphadenopathy. Biopsy shows an aggressive proliferation of small to medium-sized CD5-positive, CD23-negative B cells.Overexpression of a regulatory protein that promotes cell cycle progression from the G1 phase to the S phase.
  • A 58-year-old woman with a history of painless, waxing and waning lymphadenopathy undergoes a biopsy showing nodular aggregates of neoplastic cells lacking tingible body macrophages.Overexpression of a mitochondrial protein that inhibits the release of cytochrome c.
  • A 48-year-old man presents with early satiety and massive splenomegaly. Labs show a leukocyte count of 85,000/mm385,000/\text{mm}^3 with a full spectrum of granulocytic differentiation and low leukocyte alkaline phosphatase.Constitutive activation of a non-receptor tyrosine kinase signaling pathway.
  • A 25-year-old man presents with a rapidly expanding neck mass. Biopsy reveals uniform, medium-sized lymphoid cells with numerous mitotic figures and interspersed macrophages containing apoptotic debris.Overexpression of a nuclear transcription factor that functions as a master regulator of cellular proliferation.

Cevap

The correct pairings match Mantle cell lymphoma with cell cycle progression (Cyclin D1); Follicular lymphoma with inhibition of apoptosis (BCL-2); Chronic myeloid leukemia with activated tyrosine kinase signaling (BCR-ABL); and Burkitt lymphoma with transcription factor overexpression (c-Myc).
Each correct pairing accurately links the diagnostic clinical/pathologic features of a hematologic malignancy to the precise intracellular mechanism of its primary oncogenic driver (Cyclin D1 for Mantle Cell, BCL-2 for Follicular, BCR-ABL for CML, and c-Myc for Burkitt).

Adım Adım Çözüm

1
Analyze each clinical vignette to identify the specific hematologic malignancy based on demographics, clinical behavior, and histopathologic or laboratory findings.
Identified Mantle cell lymphoma, Follicular lymphoma, Chronic myeloid leukemia, and Burkitt lymphoma.
Accurate pathologic diagnosis is required before the underlying molecular driver can be identified.
2
Recall the characteristic chromosomal translocation associated with each identified malignancy.
Mantle cell is t(11;14); Follicular is t(14;18); CML is t(9;22); Burkitt is t(8;14).
Chromosomal translocations are the initiating events in these specific neoplastic processes.
3
Connect the specific gene product of each translocation to its functional role in the cell to find the correct match.
t(11;14) = Cyclin D1 (G1-to-S phase); t(14;18) = BCL-2 (anti-apoptotic mitochondrial protein); t(9;22) = BCR-ABL (tyrosine kinase); t(8;14) = c-Myc (transcription factor).
Understanding the downstream molecular consequence is essential for correlating the disease with its targeted cellular mechanism.

Anahtar Kavram

Molecular pathogenesis of hematologic malignancies via specific chromosomal translocations.
Bu soruyu puanla